Cell Therapy News

Researchers developed a highly accurate model that can predict which patients will achieve complete response to chimeric antigen receptor T-cell therapy for multiple myeloma.

Only a decade ago, many in oncology considered chimeric antigen receptor T-cell therapy too fringe for real-world use.

A circulating tumor DNA liquid biopsy can predict the likelihood of early disease progression among patients treated with chimeric antigen receptor T-cell therapy for advanced multiple myeloma, study results showed.

Healio | HemOnc Today is excited to announce a new physician leadership structure, which features seven Associate Medical Editors from various subspecialty areas within oncology and hematology.

Kristen M. Hege, MD, is one of those rare individuals who excels at most of her endeavors.

A novel chimeric antigen receptor T-cell therapy induced response among adults with advanced large B-cell lymphoma who relapsed after previous CAR-T, study results showed.

Patients who received chimeric antigen receptor T cells for relapsed or refractory diffuse large B-cell lymphoma feared disease progression less than those who received standard regimens, results of a cross-sectional study showed.

The FDA recently withdrew its emergency use authorization for Evusheld, a combination monoclonal antibody therapy used to prevent COVID-19 among high-risk individuals.

Idecabtagene vicleucel significantly extended PFS compared with standard regimens for adults with triple-class refractory multiple myeloma, results of the randomized phase 3 KarMMa-3 trial showed.

Brexucabtagene autoleucel continued to confer a greater than 70% complete remission rate among adults with relapsed or refractory B-cell acute lymphoblastic leukemia, results from the latest analysis of a pivotal phase 2 study showed.